YiChang HEC ChangJiang Pharmaceutical 

YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise primarily engaged in the development, manufacturing, and distribution of medicinal products. Operating within the People's Republic of China, its therapeutic expertise spans antiviral treatments, solutions for endocrine and metabolic disorders, and cardiovascular health. In addition to finished pharmaceuticals, the company produces and markets active pharmaceutical ingredients (APIs) and dedicates resources to the research and development of medical devices, novel drugs, and biotechnology. It also extends its services to include medical consulting. The company's products reach hospitals and other healthcare institutions through an established network of distributors. YiChang HEC ChangJiang Pharmaceutical has forged strategic alliances with several prominent entities, including a cooperation framework agreement with Alibaba Health Technology (China) Limited for specialized influenza projects. Other key partners encompass Jointown Pharmaceutical Group Co., Ltd., Guangdong Yihao Pharmaceutical Co., Ltd., Shenzhen HEC Industrial Development Co., Ltd., and China National Accord Medicines Corporation Ltd. Founded in Yichang, China, in 2001, the company was originally known as Yichang Changjiang Pharmaceutical Company Limited before its rebranding to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. It operates as a subsidiary under the umbrella of Guangdong HEC Technology Holding Co., Ltd.